Trump Most-Favored-Nation Pricing Rule Criticized By The AAM
Two Drug Pricing Rules Finalized Late Last Week
Mooted some time ago, the Medicare Part D Drug Rebate Rule and the Medicare Part B Most-Favored-Nation Model have now been finalized by US President Donald Trump. But US off-patent body the Association for Accessible Medicines feels “further action is necessary.”
You may also be interested in...
An International Pricing Index (IPI) model has been proposed for the US Medicare health insurance framework by US President Donald Trump and the Department of Health and Human Services (HHS), as part of efforts to bring down drug prices.
After launching in the US last year, the teriparatide product developed by Pfenex and Alvogen has been introduced in Europa, via commercialization partner Theramex, beginning with Germany.
Amneal is close to a filed pipeline of three biosimilar products in the US, while furthering ambitions in the complex generics and 505(b)(2) space, management told the virtual J.P. Morgan Healthcare Conference.